Preclinical pharmacology and safety of GT005, an investigational gene therapy targeting the complement pathway for the treatment of Geographic Atrophy

被引：0
|
作者：
Esteve-Rudd, Julian [1 ]
Francis, James [1 ]
Hughes, Jane [1 ]
Ellis, Scott [1 ]
机构：
[1] Gyroscope Therapeut Ltd, London, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2022年 / 63卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
F0097
引用
收藏
页数：2
相关论文
共 9 条
  • [1] Nonclinical Safety and Pharmacology of an Investigational Gene Therapy Targeting the Complement Pathway for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration (GT005)
    Esteve-Rudd, Julian
    Francis, James
    Hughes, Jane
    Ellis, Scott
    [J]. MOLECULAR THERAPY, 2022, 30 (04) : 137 - 138
  • [2] GT005, an AAV Gene Therapy Targeting the Alternative Pathway of the Complement System for the Treatment of Geographic Atrophy
    Tam, Lawrence C. S.
    Dreismann, Anna K.
    Joel, Josephine
    Stampoulis, Dimitris
    Gardenal, Emanuela
    Esteve-Rudd, Julian
    Hughes, Jane
    Ellis, Scott
    [J]. MOLECULAR THERAPY, 2022, 30 (04) : 77 - 77
  • [3] In vivo expression and efficacy following subretinal delivery of GT005, an investigational gene therapy for the treatment of geographic atrophy (GA)
    Stampoulis, Dimitrios
    Joel, Josephine
    Dreismann, Anna
    Gardenal, Emanuela
    Hughes, Jane
    Ellis, Scott
    Esteve-Rudd, Julian
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [4] An AAV gene therapy for the treatment of geographic atrophy by targeting the alternative pathway of the complement system
    Joel, J.
    Tam, L.
    Dreisman, A.
    Stampoulis, D.
    Gardenal, E.
    Esteve-Rudd, J.
    Ellis, S.
    [J]. HUMAN GENE THERAPY, 2022, 33 (23-24) : A52 - A53
  • [5] GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)
    Ellis, Scott
    Buchberger, Anna
    Holder, Julie
    Orhan, Elise
    Hughes, Jane
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [6] Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
    Nielsen, Jared
    MacLaren, Robert E.
    Heier, Jeffrey S.
    Steel, David
    Ivanova, Tsveta
    Sivaprasad, Sobha
    Stanga, Paulo
    Bailey, Clare
    Issa, Peter Charbel
    Mendonca, Luisa
    Francis, James
    Curtiss, Darin
    Hughes, Jane
    Waheed, Nadia K.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [7] Preclinical Safety Assessment of an Investigational Gene Replacement Therapy for the Treatment of RPE65-Mediated Inherited Retinal Dystrophies
    Wu, Weiwei
    He, Sheng
    Yang, Qi
    Yang, Chenhua
    Zhang, Jingyu
    Song, Jipeng
    Zhu, Mengke
    Shi, Linyu
    Yao, Xuan
    Yang, Hui
    [J]. MOLECULAR THERAPY, 2023, 31 (04) : 171 - 171
  • [8] Pharmacology and Safety of VY-HTT01, an AAV miRNA Gene Therapy Targeting Huntingtin for the Treatment of Huntington's Disease
    Zhou, Pengcheng
    Chen, Fen
    Wang, Xin
    Christensen, Emily
    Thompson, Jeff
    Nonnnenmacher, Mathieu
    Scheel, Maria
    Ren, Xiao-Qin
    Wang, Wei
    Zhou, Xiaochuan
    Stanek, Lisa
    Mastis, Bryan
    Pechan, Peter
    Horowitz, Eric
    Dismuke, David
    Kells, Adrian
    Gamba-Vitalo, Christina
    Hou, Jay
    Carter, Todd
    Sah, Dinah
    [J]. MOLECULAR THERAPY, 2018, 26 (05) : 15 - 15
  • [9] Preclinical safety and pharmacology of KB105, an HSV-based gene therapy vector for the treatment of autosomal recessive congenital ichthyosis (ARCI)
    Zhang, P.
    Majumdar, A.
    Freedman, C.
    Yogesha, S.
    Ramasamy, S.
    Krishnan, S.
    Agarwal, P.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S66 - S66
1